UK project to reduce PFAS pollution is awarded Stockholm Junior Water Prize
Christopher Whitfield and Wenqi (Jonathan) Zhao from the United Kingdom receive the prestigious Stockholm Junior Water Prize 2024 for their work on PFAS pollution in the Thames Basin. HRH Crown Princess Victoria of Sweden presented the winners with their award during a ceremony at World Water Week in Stockholm.
Per- and polyfluoroalkyl substances (PFAS) pollution is a growing concern worldwide. Focusing on the Thames Basin in the United Kingdom, where there are with no equitable solutions to the problem, Whitfield and Zhao developed a geospatial neural network, predicting PFAS values to within 10 percent of experimentally validated values.
For this, they were announced the winners of the Stockholm Junior Water Prize, an international competition where students between the ages of 15 and 20 present solutions to major water challenges.
Speaking on winning the prize, Zhao said, “We are very proud to have won this prize. It has been an amazing stay here in Sweden with so many new friends”.
The Jury noted that Whitfield and Zhao “find a way to take data and turn it into actionable knowledge. [They have] identified PFAS hotspots using machine learning, field tested their results, developed a cost-effective filtration system, and reached out to local governments and environmental organizations to raise awareness.”
The winners were presented with their prize during an award ceremony at World Water Week by HRH Crown Princess Victoria of Sweden, the Prize’s Official Patron.
The Diploma of Excellence was awarded to Shanni Valeria Mora Fajardo and Rosa Mendoza Sosa from Mexico for their work on how to reuse inked water with homemade filtration to produce veggie gardens.
The People’s Choice Award went to Manoel José Nunes Neto from Brazil, completing the line-up of winners.
The Stockholm Junior Water Prize has been organized every year since 1997. It is hosted by the Stockholm Water Foundation, with Xylem as Founding Partner.
“Innovation is paving the way to a more water-secure world, and the next generation are accelerating progress. The Stockholm Junior Water Prize competitors are an inspiring example of the ingenuity and passion young innovators bring to the table. On behalf of Xylem, I’d like to congratulate all those who took part in this year’s competition,” said Austin Alexander, Vice President of Sustainability and Social Impact at Xylem.
Read more about the winning projects:
- Stockholm Junior Water Prize: United Kingdom
- Diploma of Excellence: Mexico
- People’s Choice Award: Brazil
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827691002/en/
Contacts
Andreas Karlsson
Head of Communication, Stockholm International Water Institute
Email: andreas.karlsson@siwi.org, Mobile: +46 (0) 720 506078
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Adtran sets new SBTi targets for net-zero emissions9.9.2024 15:00:00 EEST | Press release
Adtran today announced its new Science Based Targets initiative (SBTi) commitments. The company aims to achieve net-zero emissions across its entire value chain by 2048, aligning with the global objective of limiting warming to 1.5°C to mitigate the most severe impacts of climate change. Adtran’s newly approved commitments include a 74.5% reduction in absolute scope 1 and 2 greenhouse gas emissions by 2032 and scope 3 emissions by 40% within the same timeframe. These science-based targets underscore Adtran’s dedication to sustainability leadership, as well as its continuous efforts to reduce its own carbon footprint and that of its customers. “Our newly approved SBTi commitments underline our steadfast commitment to climate responsibility and represent a significant step forward in our environmental efforts. When we look at the sustainability gains we’ve already made as a result of joining the SBTi, we’re in no doubt we can realize our goal of organization-wide carbon neutrality,” said
First Patients Dosed in Debiopharm's Phase III Trial (LIBELULA) Investigating Debio 4326, a 12-Month Triptorelin Formulation for Children with Central Precocious Puberty9.9.2024 15:00:00 EEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to develop innovative therapies and to improve patient quality of life, today announced the dosing of the first sentinel patients in its open-label, single-arm, multi-center Phase III study, NCT06129539 ‘A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)’.Triptorelin is an established treatment for CPP as a 1-, 3- and 6-month formulation. This new phase III study evaluating the novel 12-month triptorelin formulation is being carried out in North and South America. In pursuit of developing safe, effective, and convenient treatment options for patients, Debiopharm, is applying its expertise in extended-release formulations to achieve the first yearly injectable Gonadotropin-Releasing Hormone agonist (GnRHa). Reducing treatment burden while preserv
Scientist.com and Evotec Partner to Accelerate Drug Discovery and Development9.9.2024 14:55:00 EEST | Press release
Scientist.com, the leading research platform for the pharmaceutical industry, has announced a new partnership with Evotec SE, a leading drug discovery and development company. Through this collaboration, Evotec’s comprehensive suite of R&D services, spanning the entire drug discovery and development process, will now be available to registered users on Scientist.com’s award-winning digital marketplace. "At Evotec, our mission is to deliver high-quality, efficient, and innovative drug discovery services that advance the work of researchers developing novel treatments," said Dr. Matthias Evers, Chief Business Officer of Evotec. "By partnering with Scientist.com, we can expand our reach and empower more scientists in their efforts to bring new therapies to market." Evotec offers the Scientist.com research community access to an extensive array of proprietary technologies, including cutting-edge in vitro and in vivo pharmacology, high-throughput screening, and a comprehensive suite of next
BeiGene Announces Updates to Commercial Leadership Team9.9.2024 14:00:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Matt Shaulis as General Manager of North America, effective September 25. “We are excited to welcome Matt, who brings a wealth of global pharmaceutical experience, including leading the commercialization of blockbuster franchises at multiple multinational companies,” said John V. Oyler, Co-Founder, Chairman and CEO at BeiGene. “Matt’s management will be pivotal as we continue our leadership in hematology with BRUKINSA and replicate that success in solid tumors, with a deep and exciting pipeline of innovative therapies.” Mr. Shaulis is a global commercial executive with over 20 years of experience at biopharmaceutical companies such as Hansa Biopharma, Pfizer, Teva, Cephalon, and Johnson & Johnson. While at Pfizer, he directed the U.S. commercialization of blockbuster therapies IBRANCE® and XTANDI® as well as leading Pfizer’s acquisition and integration of Medivation. Mr
LuminUltra Acquires Legionella Testing Business from Genomadix and Inks Strategic License to Commercialize Additional Tests for Ultra-portable Molecular Diagnostic Platform9.9.2024 14:00:00 EEST | Press release
LuminUltra (luminultra.com), the global leader in applied molecular diagnostics, today announced the acquisition of the legionella testing business assets of Genomadix Inc (genomadix.com), along with rights to develop and commercialize further assays and test methods in water, energy and food and beverage markets globally using the Genomadix Cube™ qPCR (quantitative polymerase chain reaction) Platform. With this transaction, LuminUltra further expands its industry-leading portfolio of molecular testing solutions for rapid identification and quantification of the microbes within residential, commercial and industrial water systems that are responsible for causing the potentially deadly Legionnaire’s disease. When paired with its easy-to-use automated test kit, the Genomadix Cube thermocycling platform will generate results that measure the presence and quantity of Legionella contamination in under one hour with laboratory-grade sensitivity. The elegant simplicity of the system allows an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom